SCHEDULE: Point72 Reduces Stake in Bicycle Therapeutics to 3.9%

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported a 3.9% beneficial ownership stake in Bicycle Therapeutics PLC as of June 30, 2025.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported beneficial ownership of 1,860,317 American Depositary Shares (ADSs) of Bicycle Therapeutics PLC.
• Each ADS represents one Ordinary Share of Bicycle Therapeutics PLC.
• This ownership represents 3.9% of the class of securities.
• The reporting persons hold shared voting and dispositive power over all 1,860,317 ADSs.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previous filing where their ownership was likely above 5%.
• The filing explicitly states 'Ownership of 5 Percent or Less of a Class,' confirming their current stake is below this threshold.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, indicating a reduction in stake below 5%. It does not inherently convey positive or negative sentiment about the company's performance, but rather a change in an investor's position.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor's reduced stake may influence market perception and trading activity.

Key Dates

Keywords

Bicycle Therapeutics, BCYC, Point72 Asset Management, Steven A. Cohen, Beneficial Ownership, Schedule 13G, Investment, Biotechnology, Pharmaceuticals, ADSs, Ordinary Shares